Toll Free: 1-888-928-9744

Dyslipidemia - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 280 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dyslipidemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 10 Global Markets Direct Report Coverage 10 Dyslipidemia - Overview 11 Dyslipidemia - Therapeutics Development 12 Pipeline Overview 12 Pipeline by Companies 13 Pipeline by Universities/Institutes 18 Products under Development by Companies 19 Products under Development by Universities/Institutes 25 Dyslipidemia - Therapeutics Assessment 26 Assessment by Target 26 Assessment by Mechanism of Action 30 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Dyslipidemia - Companies Involved in Therapeutics Development 38 Acasti Pharma Inc 38 Akcea Therapeutics Inc 38 Allergan Plc 39 Amgen Inc 39 Arisaph Pharmaceuticals Inc 40 AstraZeneca Plc 40 BASF SE 41 BCWorld Pharm Co Ltd 41 BioRestorative Therapies Inc 42 Boryung Pharmaceutical Co Ltd 42 Cadila Pharmaceuticals Ltd 43 Cardax Inc 43 Catabasis Pharmaceuticals Inc 44 Celon Pharma SA 44 Cerenis Therapeutics Holding SA 45 Chong Kun Dang Pharmaceutical Corp 45 CJ HealthCare Corp 46 Connexios Life Sciences Pvt Ltd 46 CymaBay Therapeutics Inc 47 Daewoong Pharmaceutical Co Ltd 47 Daiichi Sankyo Company Ltd 48 Eli Lilly and Company 48 Esperion Therapeutics Inc 49 Gemphire Therapeutics Inc 49 Gilead Sciences Inc 50 GlaxoSmithKline Plc 50 Golden Biotechnology Corp 51 HanAll Biopharma Co Ltd 51 Hanmi Pharmaceuticals Co Ltd 52 Huons Co Ltd 52 Hyundai Pharmaceutical Co Ltd 53 Innovent Biologics Inc 53 IPCA Laboratories Ltd 54 Jeil Pharmaceutical Co Ltd 54 Jenrin Discovery Inc 55 JW Pharmaceutical Corp 55 Kissei Pharmaceutical Co Ltd 56 Kotobuki Pharmaceutical Co Ltd 56 Kowa Company Ltd 57 Kuhnil Pharmaceutical Co Ltd 57 Kyorin Pharmaceutical Co Ltd 58 Lipicard Technologies Ltd 58 Lipigon Pharmaceuticals AB 59 LipimetiX Development Inc 59 Lotus Pharmaceutical Co Ltd 60 Matinas BioPharma Holdings Inc 60 Merck & Co Inc 61 Nippon Chemiphar Co Ltd 61 Omeros Corp 62 Pfizer Inc 62 Pharmena SA 63 Protalix BioTherapeutics Inc 63 Regeneron Pharmaceuticals Inc 64 Samjin Pharmaceutical Co Ltd 64 Sancilio & Company Inc 65 Takeda Pharmaceutical Company Ltd 65 Tasly Pharmaceutical Group Co Ltd 66 Torrent Pharmaceuticals Ltd 66 Yuhan Corp 67 Zydus Cadila Healthcare Ltd 67 Dyslipidemia - Drug Profiles 68 (amlodipine besylate + fimasartan + rosuvastatin calcium) - Drug Profile 68 (amlodipine besylate + olmesartan medoxomil) + rosuvastatin calcium - Drug Profile 69 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 70 (amlodipine besylate + rosuvastatin calcium) - Drug Profile 71 (amlodipine besylate + valsartan)+ atorvastatin calcium - Drug Profile 72 (amlodipine maleate + rosuvastatin calcium + telmisartan) - Drug Profile 73 (atorvastatin calcium + choline fenofibrate) - Drug Profile 74 (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 75 (atorvastatin calcium + metformin hydrochloride XR) - Drug Profile 76 (atorvastatin calcium IR + losartan potassium DR) - Drug Profile 77 (candesartan cilexetil + rosuvastatin calcium) - Drug Profile 78 (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79 (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 80 (nebivolol hydrochloride + rosuvastatin calcium) - Drug Profile 81 (pitavastatin + valsartan) - Drug Profile 82 4655-K09 - Drug Profile 83 AC-261066 - Drug Profile 84 AEM-28 - Drug Profile 85 AEM-2802 - Drug Profile 87 AEM-2814 - Drug Profile 88 ALN-AC3 - Drug Profile 89 ALN-ANG - Drug Profile 90 AMG-899 - Drug Profile 91 anacetrapib - Drug Profile 93 Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 95 antroquinonol - Drug Profile 96 ARGX-116 - Drug Profile 98 ARI-3037MO - Drug Profile 99 bempedoic acid - Drug Profile 101 bezafibrate SR - Drug Profile 113 BioE-1115 - Drug Profile 115 BKC-007 - Drug Profile 116 BSN-272 - Drug Profile 117 C-3 - Drug Profile 118 CAT-2000 Series - Drug Profile 119 CAT-2003 - Drug Profile 120 CDR-267F018 - Drug Profile 123 CDX-085 - Drug Profile 124 centatin - Drug Profile 127 CER-209 - Drug Profile 128 CKD-519 - Drug Profile 129 CNX-013B2 - Drug Profile 131 DF-461 - Drug Profile 132 Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 133 DS-9001 - Drug Profile 134 DWJ-1330 - Drug Profile 136 etanercept biosimilar - Drug Profile 137 evinacumab - Drug Profile 139 gemcabene calcium - Drug Profile 141 GSK-2041706 - Drug Profile 145 HCP-1105 - Drug Profile 146 HOB-071 - Drug Profile 147 HU-012 - Drug Profile 148 IBI-306 - Drug Profile 149 icosabutate - Drug Profile 150 IMMH-007 - Drug Profile 152 IONIS-ANGPTL3LRx - Drug Profile 153 IONIS-APOCIIILRX - Drug Profile 155 JD-2000 Series - Drug Profile 156 JD-5000 Series - Drug Profile 157 JD-5006 - Drug Profile 158 JD-5037 - Drug Profile 159 JD-6000 Series - Drug Profile 160 JS-002 - Drug Profile 161 K-312 - Drug Profile 162 KI-1107 - Drug Profile 163 KKM-1201 - Drug Profile 164 KT-6971 - Drug Profile 165 KTA-439 - Drug Profile 166 leucine + niacin - Drug Profile 167 liothyronine sodium - Drug Profile 168 LP-071 - Drug Profile 169 LT-5421 - Drug Profile 170 LT-5423 - Drug Profile 171 LTPO-3FA - Drug Profile 172 LY-3202328 - Drug Profile 173 MAT-9001 - Drug Profile 174 metformin hydrochloride + rosuvastatin calcium - Drug Profile 176 MN-002 - Drug Profile 177 NC-2400 - Drug Profile 179 ND-630 - Drug Profile 180 ND-654 - Drug Profile 182 NKPL-66 - Drug Profile 185 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 190 omega-3-carboxylic acids - Drug Profile 191 pemafibrate - Drug Profile 196 peroxibrate - Drug Profile 199 PF-06427878 - Drug Profile 200 Protein for Dislipidemia, Obesity and Type 2 Diabetes - Drug Profile 201 Recombinant ApoE4 for Dyslipidemia - Drug Profile 202 REGN-1001 - Drug Profile 203 saroglitazar - Drug Profile 204 SC-401 - Drug Profile 207 seladelpar - Drug Profile 208 SJP-1603 - Drug Profile 212 Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 213 Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 214 Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile 215 Small Molecule for Cardiovascular and Metabolic Diseases - Drug Profile 216 Small Molecule for Hypertriglyceridaemia - Drug Profile 217 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 218 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 219 Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 220 Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 221 Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile 222 Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile 223 Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 224 Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease - Drug Profile 225 Small Molecules to Target GPR146 for Metabolic Disorders - Drug Profile 226 SPX-8522876 - Drug Profile 227 Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile 228 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 230 Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 231 TRC-210258 - Drug Profile 232 TRIA-662 - Drug Profile 233 TSL-1516 - Drug Profile 235 volanesorsen sodium - Drug Profile 236 ZLN-005 - Drug Profile 243 ZLN-024 - Drug Profile 244 ZYH-7 - Drug Profile 245 Dyslipidemia - Dormant Projects 246 Dyslipidemia - Discontinued Products 255 Dyslipidemia - Product Development Milestones 259 Featured News & Press Releases 259 Appendix 271 Methodology 271 Coverage 271 Secondary Research 271 Primary Research 271 Expert Panel Validation 271 Contact Us 271 Disclaimer 272
List of Tables
Number of Products under Development for Dyslipidemia, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2017 Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2017 Dyslipidemia - Pipeline by Allergan Plc, H1 2017 Dyslipidemia - Pipeline by Amgen Inc, H1 2017 Dyslipidemia - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017 Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2017 Dyslipidemia - Pipeline by BASF SE, H1 2017 Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2017 Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2017 Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 Dyslipidemia - Pipeline by Cardax Inc, H1 2017 Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017 Dyslipidemia - Pipeline by Celon Pharma SA, H1 2017 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2017 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 Dyslipidemia - Pipeline by CJ HealthCare Corp, H1 2017 Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H1 2017 Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2017 Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H1 2017 Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H1 2017 Dyslipidemia - Pipeline by Gilead Sciences Inc, H1 2017 Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2017 Dyslipidemia - Pipeline by Golden Biotechnology Corp, H1 2017 Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H1 2017 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Dyslipidemia - Pipeline by Huons Co Ltd, H1 2017 Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Innovent Biologics Inc, H1 2017 Dyslipidemia - Pipeline by IPCA Laboratories Ltd, H1 2017 Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Jenrin Discovery Inc, H1 2017 Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H1 2017 Dyslipidemia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Kowa Company Ltd, H1 2017 Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H1 2017 Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H1 2017 Dyslipidemia - Pipeline by LipimetiX Development Inc, H1 2017 Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, H1 2017 Dyslipidemia - Pipeline by Merck & Co Inc, H1 2017 Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017 Dyslipidemia - Pipeline by Omeros Corp, H1 2017 Dyslipidemia - Pipeline by Pfizer Inc, H1 2017 Dyslipidemia - Pipeline by Pharmena SA, H1 2017 Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H1 2017 Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Dyslipidemia - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017 Dyslipidemia - Pipeline by Sancilio & Company Inc, H1 2017 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017 Dyslipidemia - Pipeline by Yuhan Corp, H1 2017 Dyslipidemia - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Dyslipidemia - Dormant Projects, H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..1), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..2), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..3), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..4), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..5), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..6), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..7), H1 2017 Dyslipidemia - Dormant Projects, H1 2017 (Contd..8), H1 2017 Dyslipidemia - Discontinued Products, H1 2017 Dyslipidemia - Discontinued Products, H1 2017 (Contd..1), H1 2017 Dyslipidemia - Discontinued Products, H1 2017 (Contd..2), H1 2017 Dyslipidemia - Discontinued Products, H1 2017 (Contd..3), H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify